Author-it Software Corporation announced the pharmaceutical company Boehringer Ingelheim selected Docuvera to enable medical authors to build clinical and regulatory documents from pre-approved components of medical content. Docuvera gives Boehringer Ingelheim a platform for authors to create and update pharmaceutical documentation.
Docuvera, developed specifically for the Life Sciences market, combines component authoring, review and approval, publishing, and audit trails on a single platform allowing BioPharmas to collaboratively author documents, conduct targeted reviews of modified components, and publish Word, PDF or HTML documents from a single source. And, when source content changes, modifications cascade to documents reusing component content.
“For years, BioPharmas have searched for a solution to the inefficient copying-and-pasting of documents using traditional desktop software. Unfortunately, their only option was complicated software requiring medical authors to think like software programmers,” said Paul Reid, CEO of Author-it. “With Docuvera, medical authors now have an intuitive system that feels as familiar as desktop software, but also allows them to create/update, review/approve and publish documents in a fraction of the time as traditional methods.”